Cost-effectiveness of camrelizumab plus chemotherapy versus chemotherapy alone as first-line therapy in advanced or metastatic esophageal squamous cell carcinoma

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. DOI:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. DOI:10.3322/caac.21338
   PubMed Web of Science ®Google Scholar
• Huang J, Koulaouzidis A, Marlicz W, et al. Global burden, risk factors, and trends of esophageal cancer: an analysis of cancer registries from 48 Countries. Cancers (Basel). 2021;13(141):1–16. DOI:10.3390/cancers13010141
   Google Scholar
• International agency for research on cancer: globocan 2020, China [Internet]. [cited Aug 4 2022]. Available from:https://gco.iarc.fr/today/data/factsheets/populations/160-china-fact-sheets.pdf.
   Google Scholar
• Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541(7636):169–175. DOI:10.1038/nature20805.
   PubMed Web of Science ®Google Scholar
• CSCO. Guidelines of Chinese Society of Clinical Oncology (CSCO): esophageal cancer. Beijing: People’s Medical Publishing House Co., Ltd; 2022.
   Google Scholar
• NCCN: NCCN clinical practice guidelines in oncology: esophageal and esophagogastric junction cancers（Version 4.2022） [Internet]. [cited 2022 Sep 11]. Available from:https://guide.medlive.cn/guideline/26758.
   Google Scholar
• Enomoto N, Yamada K, Terayama M, et al. Current status of immune checkpoint inhibitor therapy for advanced esophageal squamous cell carcinoma. Glob Health Med. 2021;3(6):378–385. DOI:10.35772/ghm.2020.01112
   PubMedGoogle Scholar
• Puhr HC, Preusser M, Ilhan-Mutlu A. Immunotherapy for esophageal cancers: what is practice changing in 2021? Cancers (Basel). 2021;13(18):4632.
   PubMed Web of Science ®Google Scholar
• Li D, Tang L, Hu J, et al. Immune checkpoint inhibitors’ combination therapy as first-Line treatment in advanced esophageal squamous cell carcinoma: a meta-Analysis. J Cancer Res Clin Oncol. 2023;149(3):933–939. DOI:10.1007/s00432-022-04066-2
   PubMed Web of Science ®Google Scholar
• Luo H, Lu J, Bai Y, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA-J Am Med Assoc. 2021;326(10):916–925. DOI:10.1001/jama.2021.12836
   PubMed Web of Science ®Google Scholar
• Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-Label, parallel-Group, randomised, phase 2 trial. Lancet Oncol. 2020;21(4):571–580. DOI:10.1016/S1470-2045(20)30011-5
   PubMed Web of Science ®Google Scholar
• Zhou C, Chen G, Huang Y, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-Naive patients with advanced non-Squamous non-Small-Cell lung cancer (Camel): a randomised, open-Label, multicentre, phase 3 trial. Lancet Resp Med. 2021;9(3):305–314. DOI:10.1016/S2213-2600(20)30365-9
   PubMed Web of Science ®Google Scholar
• Zhu Y, Liu K, Ding D, et al. Pembrolizumab plus chemotherapy as first-Line treatment for advanced esophageal cancer: a cost-effectiveness analysis. Adv Ther. 2022;39(6):2614–2629. DOI:10.1007/s12325-022-02101-9
   PubMed Web of Science ®Google Scholar
• Zhang PF, Xie D, Li Q. Cost-Effectiveness analysis of nivolumab in the second-Line treatment for advanced esophageal squamous cell carcinoma. Future Oncol. 2020;16(17):1189–1198.
   PubMed Web of Science ®Google Scholar
• Wang Y, Huang Y, Shao H. Cost-Effectiveness of pembrolizumab versus chemotherapy for advanced Esophageal Squamous Cell Carcinoma (ESCC) as the second-Line treatment among the Chinese population. Value Health. 2021;24:S32.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Li Y, Wang LXW. Cost-Effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-Line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. Int J Clin Pharm Net. 2022;44(2):499–506.
   PubMed Web of Science ®Google Scholar
• Gong J, Su D, Shang J, et al. Cost-Effectiveness of tislelizumab versus docetaxel for previously treated advanced non-Small-Cell lung cancer in China. Front Pharmacol. 2022;13:830380.
   PubMed Web of Science ®Google Scholar
• Zhang SW, Zheng RS, Zuo TT, et al. Mortality and survival analysis of esophageal cancer in China. Chin J Oncol. 2016;38(9):709–715. DOI:10.3760/cma.j.issn.0253-3766.2016.09.014
   Google Scholar
• Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12(1):9. DOI:10.1186/1471-2288-12-9
   PubMed Web of Science ®Google Scholar
• Ishak KJ, Kreif N, Benedict A, et al. Overview of parametric survival analysis for health-Economic applications. Pharmacoeconomics. 2013;31(8):663–675. DOI:10.1007/s40273-013-0064-3
   PubMed Web of Science ®Google Scholar
• Akaike H. A new look at the statistical model identification. IEEE T Automat Contr. 1974;19(6):716–723.
   Web of Science ®Google Scholar
• Raftery AE. Bayesian model selection in social research. Sociological Methodol. 1995;25:111–163.
   Web of Science ®Google Scholar
• Roche: Parametric survival analysis using the flexsurvplus package: understanding the theory [Internet]. [cited 2022 Aug 21]. Available from:https://iain-t-bennett-roche.github.io/flexsurvPlus/articles/Model_theory.html.
   Google Scholar
• Al-Batran SE, Van Cutsem E, Oh SC, et al. Quality-of-Life and performance status results from the phase III rainbow study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Ann Oncol. 2016;27(4):673–679. DOI:10.1093/annonc/mdv625
   PubMed Web of Science ®Google Scholar
• Nafees B, Lloyd AJ, Dewilde S, et al. Health state utilities in non-Small cell lung cancer: an international study. Asia-Pac J Clin Onco. 2017;13(5):E195–203. DOI:10.1111/ajco.12477
   PubMed Web of Science ®Google Scholar
• NHSA: National Reimbursement Drug List (NRDL) [Internet]. [cited 2023 Apr 26]. Available from:http://www.nhsa.gov.cn/art/2023/1/18/art_14_10082.html.
   Google Scholar
• Yaozhi Net: yaoZH Database: marketing Information, volume-based Procurement [Internet]. [cited 2022 Aug 13]. Available from:https://db.yaozh.com/dailiangcaigou.
   Google Scholar
• Yaozhi Net: Drugdataexpy: national essential drugs list [Internet]. [cited 2022 Aug 13]. Available from:https://data.yaozh.com/basicdir.
   Google Scholar
• Yang F, Fu Y, Kumar A, et al. Cost-Effectiveness analysis of camrelizumab in the second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China. Ann Transl Med. 2021;9(15):1226. DOI:10.21037/atm-21-1803
   PubMed Web of Science ®Google Scholar
• Liu GE, Hu SL, Wu JH, et al. China guidelines for pharmacoeconomic evaluations. Beinjing: China Market Press; 2020.
   Google Scholar
• China CDC. Report on the nutrition and chronic diseases status of Chinese residents. Beijing: People’s Medical Publishing House; 2020.
   Google Scholar
• Liu Q, Luo X, Peng L, et al. Nivolumab versus docetaxel for previously treated advanced non-Small cell lung cancer in China: a cost-Effectiveness analysis. Clin Drug Invest. 2019;40(2):129–137. DOI:10.1007/s40261-019-00869-3
   Web of Science ®Google Scholar
• National Bureau of Statistics of China (NBS): National Data [Internet]. [cited 2022 Mar 28]. Available from:https://data.stats.gov.cn/english/easyquery.htm?cn=C01.
   Google Scholar
• Craig BA, Black MA. Incremental cost-effectiveness ratio and incremental net-health benefit: two sides of the same coin. Expert Rev Pharm Out. 2001;1(1):37–46.
   Google Scholar
• Edlin R, McCabe C, Hulme C, et al. Cost effectiveness modelling for health technology assessment a practical course. Switzerland: Adis, Cham; 2015.
   Google Scholar
• Zhang Q, Wu P, He X, et al. Cost-Effectiveness analysis of camrelizumab vs. placebo added to chemotherapy as first-Line therapy for advanced or metastatic esophageal squamous cell carcinoma in China. Front Oncol. 2021;11:790373.
   PubMed Web of Science ®Google Scholar
• Chen ST, Chen JJ, Wang LD, et al. The study of health related quality of life of patients with esophagus. Acta Universitatis Medicinalis Nanjing (Social Sciences). 2016;16(1):24–28.
   Google Scholar
• Shiroiwa T, Fukuda T, Shimozuma K. Cost-Effectiveness analysis of trastuzumab to treat HER2-Positive advanced gastric cancer based on the randomised ToGA Trial. Br J Cancer. 2011;105(9):1273–1278.
   PubMed Web of Science ®Google Scholar
• Qu T, Zhong Y, Zhang S, et al. Cost-Effectiveness of pembrolizumab plus platinum and fluoropyrimidine-Based chemotherapy as first-Line treatment of advanced esophageal cancer in the United States. Ann Oncol. 2021;32:S1059–60.
   Web of Science ®Google Scholar
• Liu S, Dou L, Wang K, et al. Cost-Effectiveness analysis of nivolumab combination therapy in the first-Line treatment for advanced esophageal squamous-Cell carcinoma. Front Oncol. 2022;12:899966.
   PubMed Web of Science ®Google Scholar
• Wang Y, Shi J, Du L, et al. Health-Related quality of life in patients with esophageal cancer or precancerous lesions assessed by EQ-5D: a multicenter cross-Sectional study. Thorac Cancer. 2020;11(4):1076–1089. DOI:10.1111/1759-7714.13368
   PubMed Web of Science ®Google Scholar
• Cai D, Shi S, Jiang S, et al. Estimation of the cost-Effective threshold of a quality-Adjusted life year in China based on the value of statistical life. Eur J Health Econ. 2022;23(4):607–615. DOI:10.1007/s10198-021-01384-z
   PubMed Web of Science ®Google Scholar
• Ochalek J, Wang H, Gu Y, et al. Informing a Cost-effectiveness threshold for health technology assessment in China: a marginal productivity approach. Pharmacoeconomics. 2020;38(12):1319–1331. DOI:10.1007/s40273-020-00954-y
   PubMed Web of Science ®Google Scholar
• Thokala P, Ochalek J, Leech AA, et al. Cost-Effectiveness thresholds: the past, the present and the future. Pharmacoeconomics. 2018;36(5):509–522. DOI:10.1007/s40273-017-0606-1
   PubMed Web of Science ®Google Scholar
• Tzanetakos C, Gourzoulidis G. Does a standard cost-Effectiveness threshold exist? The case of greece. Value Health Reg Iss. 2023;36:18–26.
   PubMedGoogle Scholar
• Woods B, Revill P, Sculpher M, et al. Country-Level cost-Effectiveness thresholds: initial estimates and the need for further research. Value Health. 2016;19(8):929–935. DOI:10.1016/j.jval.2016.02.017
   PubMed Web of Science ®Google Scholar
• Cameron D, Ubels J, Norström F. On what basis are medical cost-Effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review. Global Health Action. 2018;11(1):1447828.
   PubMed Web of Science ®Google Scholar
• Paulden M. Recent amendments to NICE’s value-based assessment of health technologies: implicitly inequitable? Expert Rev Pharm Out. 2017;17(3):239–242.
   Google Scholar
• ICER: 2020-2023 Value assessment framework [Internet]. [cited 2022 Nov 16]. Available from:http://icer.org/wp-content/uploads/2020/10/ICER_2020_2023_VAF_102220.pdf.
   Google Scholar
• Lakdawalla DN, Phelps CE. Health technology assessment with diminishing returns to health: the GeneraLized Risk-Adjusted Cost-Effectiveness (GRACE) approach. Value Health. 2021;24(2):244–249.
   PubMed Web of Science ®Google Scholar
• Zhang K, Garau M: International cost-Effectiveness thresholds and modifiers for HTA decision making [Internet]. [cited 2022 Nov 25]. Available from:https://www.ohe.org/publications/international-cost-effectiveness-thresholds-and-modifiers-hta-decision-making.
   Google Scholar